RedHill Biopharma Announces Agreement with NIAID to Evaluate RHB-107 Against COVID-19GlobeNewsWire • 04/20/20
Additional Update on COVID-19 Compassionate Use with Opaganib in Israel Provided by RedHill BiopharmaGlobeNewsWire • 04/17/20
RedHill Biopharma Provides Initial Update from its Opaganib COVID-19 Compassionate Use Program in IsraelGlobeNewsWire • 04/13/20
RedHill Biopharma Announces Approval of Compassionate Use of Opaganib for COVID-19 in ItalyGlobeNewsWire • 04/06/20
RedHill Biopharma Announces First COVID-19 Patient Treated with Opaganib in Israel Under Compassionate UseGlobeNewsWire • 04/06/20
RedHill Biopharma Announces Preferred Position for Talicia® on Express Scripts National Preferred Formulary Effective March 13, 2020GlobeNewsWire • 03/13/20
RedHill Biopharma Ltd. (RDHL) CEO Dror Ben-Asher on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/04/20
RedHill Biopharma Provides Full-Year 2019 Financial Results and Operational HighlightsGlobeNewsWire • 03/04/20
RedHill Biopharma Enters $115 Million Non-Dilutive Financing Agreement with HealthCare Royalty PartnersGlobeNewsWire • 02/25/20
RedHill Biopharma Launches H. pylori Disease State Awareness Field Campaign Ahead of Talicia® LaunchGlobeNewsWire • 01/27/20
RedHill Biopharma to Focus Commercial Efforts on Talicia® and Aemcolo®; Discontinuing Promotion of Legacy ProductsGlobeNewsWire • 01/21/20
RedHill Biopharma Regains Rights to its Proprietary Bowel Preparation RHB-106GlobeNewsWire • 01/02/20
RedHill Biopharma Initiates U.S. Promotion of Aemcolo® for Travelers’ DiarrheaGlobeNewsWire • 12/17/19
RedHill Biopharma Ltd. (RDHL) CEO Dror Ben-Asher on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/19/19
Dual-Listed RedHill Biopharma to Voluntarily Delist from Tel-Aviv Stock ExchangeGlobeNewsWire • 11/15/19